Back
2019
Deal

USD 100 million debt financing by Hercules Capital to Urovant Sciences

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to USD 100 million. Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes.

VISCHER advised Urovant Sciences as Swiss counsel. The VISCHER Team included Dr. Adrian Dörig (Partner, Banking & Finance), Ruben Masar (Senior Associate, Corporate), Julian Merz (Associate, Banking & Finance) and Christoph Niederer (Partner, Tax).

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions